Today, Paxman publishes the November issue of its newsletter aimed at shareholders, investors and other interested parties.
This month’s issue highlights that The US Centers for Medicare & Medicaid Services (CMS) has reassigned payment for scalp cooling for Medicare claims filed using CPT code 0662T to New Technology APC 1520, with a National Average Payment of 1,850.50 USD, effective January 1, 2022. This is a significant step forward for cancer chemotherapy patients across the US that will ensure strong expansion of patient access to scalp cooling.
The newsletter also includes information on the opening of a clinical trial with National University Hospital, Singapore, in collaboration with The N.1 Institute for Health, National University of Singapore, to investigate the safety and tolerability of limb cryocompression in preventing of chemotherapy-induced peripheral neuropathy (CIPN) via the newly developed Paxman Cryocompression System (PCCS) in healthy subjects and cancer patients, several orders and installs in the UK and internationally, and the appointment of a new distribution partner for Uruguay.
To read the newsletter and subscribe for upcoming issues, follow this link:
Paxman’s investor newsletter is published monthly as a part of the company’s effort to strengthen its market communication together with the IR communication agency Honeybadger. Every published issue of the newsletter is available on Paxman’s website for investors, www.paxman.se. The company encourages feedback and requests on topics for upcoming issues of the newsletter.
